BRAF and acral lentiginous melanoma: Immune checkpoint blockade therapies—in particular, anti-PD-1 antibodies—showed great potential in acral melanomas: survival was longer in patients treated with immune checkpoint inhibitors as the first-line treatment than in patients receiving other systemic therapies (e.g., BRAF/MEK inhibitors and chemotherapy).